Strategies for use of a limited influenza vaccine supply

JAMA

Volumn 293, Issue 2, 2005, Pages 229-232

  Cosgrove, Sara E ^a,e   Fishman, Neil O ^b   Talbot, Thomas R ^c   Woeltje, Keith F ^d   Schaffner, William ^c   Fraser, Victoria J ^d   McMillan, Julia A ^a   Perl, Trish M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE;

CHRONIC DISEASE; HEALTH CARE PLANNING; HEALTH PRACTITIONER; HOSPITAL INFECTION; HUMAN; IMMUNE RESPONSE; INFLUENZA; INFLUENZA VACCINATION; INJECTION; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; VACCINE PRODUCTION; VIRUS TRANSMISSION;

EID: 11844286848     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.293.2.229     Document Type: Note

References (22)

1. Sartor C, Zandotti C, Romain F, et al. Disruption of services in an internal medicine unit due to a nosocomial influenza outbreak. Infect Control Hosp Epidemiol. 2002;23:615-619.
2. Potter J, Stott DJ, Roberts MA, et al. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis. 1997;175:1-6.
3. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA. 2000;284:1655-1663.
4. Wilde JA, McMillan JA, Serwint J, Butta J, O'Riordan MA, Steinhoff MC. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA. 1999;281:908-913.
5. Department of Health and Human Services Centers for Disease Control and Prevention Web site. Who should get the flu vaccine this season. Available at: http: //www.cdc.gov/flu/protect/0405shortage.htm. Accessed November 1, 2004.
6. Department of Health and Human Services Centers for Disease Control and Prevention Web site. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices expands priority groups for inactivated influenza vaccination. Available at http://www.cdc.gov/od/oc/media/pressrel/ r041217 .htm. Accessed December 21, 2004.
7. Hayden FG. Prevention and treatment of influenza in immunocompromised patients. Am J Med. 1997;102:55-60.
8. Treanor J, Keitel W, Belshe R, et al. Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine. 2002;20:1099-1105.
9. Belshe RB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med. 2004;351:2286-2294.
10. Kenney RT, Frech SA, Muenz LR, Villar CP, Clenn CM. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med. 2004;351:2295-2301.
11. Becton, Dickinson and Company Web site. BD Integra .3ms Syringe [whitepaper]. Available at: http://bd.com/safety/pdfs/ Low_Waste_Space_whitepaper_0554.pdf. Accessed November 11, 2004.
12. Belshe RB, Nichol KL, Black SB, et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. Clin Infect Dis. 2004;39:920-927.
13. Jackson LA, Holmes SJ, Mendelman PM, Muggins L, Cho I, Rhorer J. Safety of a trivalent live attenuated intranasal influenza vaccine, flumist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine. 1999;17:1905-1909.
14. King JC Jr, Treanor J, Fast PE, et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV- infected adults. J Infect Dis. 2000;181:725-728.
15. King JC Jr, Fast PE, Zangwill KM, et al. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J. 2001;20:1124-1131.
16. Talbot TR, Cracker DD, Peters J, Doersam JK, Wright PF, Edwards KM. Degree and duration of mucosal shedding following use of the trivalent intranasal live attenuated influenza vaccine in adults. Paper presented at: The Society for Healthcare Epidemiology in America 14th Annual Meeting; April 18, 2004; Philadelphia, Pa. Abstract 54.
17. Murphy BR, Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol. 2002;15:295-323.
18. Keitel WA, Couch RB, Quarles JM, Cate TR, Baxter B, Maassab HF. Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults. J Infect Dis. 1993;167:305-311.
19. Vesikari T, Karvonen A, Korhonen T, et al. A randomized, double-blind, placebo-controlled trial of the safety, transmissibility and phenotypic stability of a live, attenuated, cold adapted influenza virus vaccine (Caiv-T) in children attending day care. Paper presented at: The 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago, Ill. Abstract C-450.
20. Cha TA, Kao K, Zhao J, Fast PE, Mendelman PM, Arvin A. Cenotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. J Clin Microbiol. 2000;38:839-845.
21. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2004;53(RR-6):1-40.
22. Department of Health and Human Services Centers for Disease Control and Prevention Web site. Respiratory hygiene/cough etiquette in healthcare settings. Available at: http://www.cdc.gov/flu/professionals/infectioncontrol/resphygiene .htm. Accessed November 1, 2004.